Evolving options for the treatment of metastatic breast cancer: progression-free survival as an endpoint.
about
Expression of TweakR in breast cancer and preclinical activity of enavatuzumab, a humanized anti-TweakR mAb.Comparing duration of response and duration of clinical benefit between fulvestrant treatment groups in the CONFIRM trial: application of new methodology.Use of the metastatic breast cancer progression (MBC-P) questionnaire to assess the value of progression-free survival for women with metastatic breast cancer.Issues surrounding clinical trial endpoints in solid malignancies with a focus on metastatic non-small cell lung cancer.A Delphi consensus and open debate on the role of first-line bevacizumab for HER2-negative metastatic breast cancer.
P2860
Evolving options for the treatment of metastatic breast cancer: progression-free survival as an endpoint.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 10 February 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Evolving options for the treat ...... -free survival as an endpoint.
@en
Evolving options for the treat ...... -free survival as an endpoint.
@nl
type
label
Evolving options for the treat ...... -free survival as an endpoint.
@en
Evolving options for the treat ...... -free survival as an endpoint.
@nl
prefLabel
Evolving options for the treat ...... -free survival as an endpoint.
@en
Evolving options for the treat ...... -free survival as an endpoint.
@nl
P2860
P1476
Evolving options for the treat ...... -free survival as an endpoint.
@en
P2093
Sara A Hurvitz
P2860
P304
P356
10.1016/J.CTRV.2011.01.002
P577
2011-02-10T00:00:00Z